To date, we have witnessed the paradigm-shifting roles of PSMA-targeted radiopharmaceuticals in prostate cancer patient care, as represented by [68Ga]Ga-PSMA-11 and [18F]F-DCFPyl for PET imaging and [177Lu]Lu-PSMA-617 for radiotherapy [6]. This evidence concerns the gene FOLH1 and Familial prostate cancer.